Suppr超能文献

肝细胞癌的组织诊断

Tissue diagnosis of hepatocellular carcinoma.

作者信息

Jain Deepali

机构信息

Department of Pathology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India.

出版信息

J Clin Exp Hepatol. 2014 Aug;4(Suppl 3):S67-73. doi: 10.1016/j.jceh.2014.03.047. Epub 2014 Apr 1.

Abstract

The current American Association for the Study of Liver Diseases (AASLD) guideline provides strategies for achieving the diagnosis of hepatocellular carcinoma (HCC) based on the size of liver nodules seen on surveillance imaging. For lesions less than 1 cm in size, follow-up surveillance imaging is recommended. Lesions larger than 2 cm require typical radiological hallmark on dynamic imaging. Lesions of 1-2 cm in size require typical imaging features including intense uptake of contrast during arterial phases followed by decreased enhancement during portal venous phases on at least 2 imaging modalities. In cases of atypical radiological features of the suspected lesion, tissue diagnosis either by fine needle aspiration or biopsy should be obtained. Although fine needle aspiration could give a smaller risk of seeding than biopsy, biopsy has been preferred over cytology. Percutaneous biopsy of HCC carries a potential risk of tumor seeding along the needle tract. However the risk is low and there is no clear evidence of post transplant recurrence due to needle tract seeding. Histopathologic assessment can differentiate between premalignant lesions such as dysplastic nodules and early HCC. Atypical variants of HCC can be recognized morphologically which may have associated prognostic value.

摘要

美国肝病研究学会(AASLD)现行指南提供了基于监测成像中所见肝脏结节大小实现肝细胞癌(HCC)诊断的策略。对于直径小于1厘米的病变,建议进行随访监测成像。直径大于2厘米的病变需要动态成像具有典型的放射学特征。直径为1-2厘米的病变需要典型的成像特征,包括在至少两种成像模式下动脉期对比剂强烈摄取,随后门静脉期强化减弱。对于疑似病变的非典型放射学特征病例,应通过细针穿刺抽吸或活检进行组织诊断。虽然细针穿刺抽吸比活检导致种植的风险更小,但活检一直比细胞学检查更受青睐。HCC的经皮活检存在沿针道肿瘤种植的潜在风险。然而,这种风险较低,且没有明确证据表明移植后复发是由针道种植引起的。组织病理学评估可以区分发育异常结节等癌前病变和早期HCC。HCC的非典型变体可以通过形态学识别,这可能具有相关的预后价值。

相似文献

1
Tissue diagnosis of hepatocellular carcinoma.
J Clin Exp Hepatol. 2014 Aug;4(Suppl 3):S67-73. doi: 10.1016/j.jceh.2014.03.047. Epub 2014 Apr 1.
2
Nodule in Liver: Investigations, Differential Diagnosis and Follow-up.
J Clin Exp Hepatol. 2014 Aug;4(Suppl 3):S57-62. doi: 10.1016/j.jceh.2014.06.010. Epub 2014 Jul 23.
4
Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance.
Ann Hepatol. 2019 Mar-Apr;18(2):318-324. doi: 10.1016/j.aohep.2018.09.002. Epub 2019 Apr 17.
5
Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B.
JHEP Rep. 2021 Sep 16;3(6):100364. doi: 10.1016/j.jhepr.2021.100364. eCollection 2021 Dec.
7
Fine needle aspiration biopsy of hepatocellular carcinoma and hepatocellular nodular lesions: role, controversies and approach to diagnosis.
Cytopathology. 2011 Oct;22(5):287-305. doi: 10.1111/j.1365-2303.2011.00882.x. Epub 2011 Jul 18.
8
Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma.
J Hepatol. 2014 May;60(5):995-1001. doi: 10.1016/j.jhep.2014.01.006. Epub 2014 Jan 22.
10
Liver transplantation for hepatocellular carcinoma: role of biopsy.
Liver Transpl. 2007 Nov;13(11 Suppl 2):S17-23. doi: 10.1002/lt.21326.

引用本文的文献

1
Recent Advances in Ablative Therapies for HCC.
J Clin Exp Hepatol. 2025 Sep-Oct;15(5):102592. doi: 10.1016/j.jceh.2025.102592. Epub 2025 May 17.
2
Current Trends and Impact of Liver Biopsy on Survival in Hepatocellular Carcinoma: A Korean Multicenter Analysis.
Diagnostics (Basel). 2025 Mar 24;15(7):818. doi: 10.3390/diagnostics15070818.
5
Radiological-histopathological discordance in patients transplanted for HCC and its impact on post-transplant outcomes.
Cancer Med. 2023 Jul;12(14):15011-15025. doi: 10.1002/cam4.6161. Epub 2023 Jun 16.
6
Pedunculated hepatocellular carcinoma masquerading as a giant GIST: A case report.
Int J Surg Case Rep. 2023 Apr;105:108102. doi: 10.1016/j.ijscr.2023.108102. Epub 2023 Apr 1.
7
The Course of LIRADS 3 and 4 Hepatic Abnormalities as Correlated With Explant Pathology: A Single Center Experience.
J Clin Exp Hepatol. 2022 Jul-Aug;12(4):1048-1056. doi: 10.1016/j.jceh.2022.02.005. Epub 2022 Mar 9.
8
Fontan Liver Lesions: Not Always HCC.
JACC Case Rep. 2019 Aug 21;1(2):175-178. doi: 10.1016/j.jaccas.2019.05.031. eCollection 2019 Aug.

本文引用的文献

2
Sal-like protein 4: an epithelial and germ cell marker.
Hum Pathol. 2013 Jul;44(7):1453. doi: 10.1016/j.humpath.2013.03.015.
3
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma.
N Engl J Med. 2013 Jun 13;368(24):2266-76. doi: 10.1056/NEJMoa1300297.
4
Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers.
Hepatology. 2013 Apr;57(4):1469-83. doi: 10.1002/hep.26159. Epub 2013 Mar 6.
8
Arginase-1 is a more sensitive marker of hepatic differentiation than HepPar-1 and glypican-3 in fine-needle aspiration biopsies.
Cancer Cytopathol. 2012 Aug 25;120(4):230-7. doi: 10.1002/cncy.21190. Epub 2012 Mar 20.
9
The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis.
Hum Pathol. 2012 May;43(5):769; author reply 769-70. doi: 10.1016/j.humpath.2011.12.016. Epub 2012 Feb 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验